Merus (MRUS) News Today $46.98 -1.79 (-3.67%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Merus (MRUS) Gets a Buy from CitiMarch 22 at 6:20 AM | markets.businessinsider.comBuy Rating on Merus: Promising Potential of Petosemtamab in Combination with PD-1 Therapy for Head and Neck CancerMarch 21, 2025 | tipranks.comGuggenheim Reiterates Buy Rating for Merus (NASDAQ:MRUS)March 20, 2025 | americanbankingnews.comMerus (NASDAQ:MRUS) Earns "Buy" Rating from GuggenheimGuggenheim reissued a "buy" rating and issued a $109.00 price target on shares of Merus in a research report on Tuesday.March 19, 2025 | marketbeat.comMerus (NASDAQ:MRUS) Shares Gap Up - Still a Buy?Merus (NASDAQ:MRUS) Shares Gap Up - Should You Buy?March 18, 2025 | marketbeat.comMerus (NASDAQ:MRUS) Given Average Recommendation of "Buy" by BrokeragesShares of Merus (NASDAQ:MRUS - Get Free Report) have received an average recommendation of "Buy" from the sixteen research firms that are currently covering the company, Marketbeat reports. Fourteen investment analysts have rated the stock with a buy rating and two have issued a strong buy ratingMarch 13, 2025 | marketbeat.comBank of America Has Lowered Expectations for Merus (NASDAQ:MRUS) Stock PriceBank of America reduced their price target on shares of Merus from $73.00 to $70.00 and set a "buy" rating for the company in a research note on Monday.March 11, 2025 | marketbeat.comBank of America Securities Remains a Buy on Merus (MRUS)March 10, 2025 | markets.businessinsider.comMerus (NASDAQ:MRUS) Short Interest UpdateMerus (NASDAQ:MRUS - Get Free Report) was the target of a large decline in short interest in the month of February. As of February 15th, there was short interest totalling 6,640,000 shares, a decline of 13.5% from the January 31st total of 7,680,000 shares. Based on an average daily trading volume, of 629,600 shares, the short-interest ratio is currently 10.5 days.March 7, 2025 | marketbeat.comStifel Nicolaus Sticks to Its Buy Rating for Merus (MRUS)March 6, 2025 | markets.businessinsider.comHC Wainwright Reaffirms Buy Rating for Merus (NASDAQ:MRUS)HC Wainwright reaffirmed a "buy" rating and issued a $85.00 price target on shares of Merus in a research note on Monday.March 3, 2025 | marketbeat.comWilliam Blair Estimates Merus' FY2028 Earnings (NASDAQ:MRUS)Merus (NASDAQ:MRUS - Free Report) - Stock analysts at William Blair issued their FY2028 earnings estimates for Merus in a research note issued to investors on Friday, February 28th. William Blair analyst M. Phipps forecasts that the biotechnology company will post earnings of ($3.58) per share foMarch 3, 2025 | marketbeat.comMerus' (MRUS) Outperform Rating Reaffirmed at William BlairWilliam Blair reissued an "outperform" rating on shares of Merus in a research note on Friday.March 1, 2025 | marketbeat.comTruist Financial Sticks to Their Buy Rating for Merus (MRUS)March 1, 2025 | markets.businessinsider.comAnalyst Forecasts Just Became More Bearish On Merus N.V. (NASDAQ:MRUS)March 1, 2025 | finance.yahoo.comMerus (NASDAQ:MRUS) Given New $83.00 Price Target at Needham & Company LLCNeedham & Company LLC reduced their price objective on shares of Merus from $85.00 to $83.00 and set a "buy" rating on the stock in a research note on Friday.March 1, 2025 | marketbeat.comMerus (NASDAQ:MRUS) Posts Quarterly Earnings Results, Beats Estimates By $0.48 EPSMerus (NASDAQ:MRUS - Get Free Report) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.89) by $0.48. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%.February 28, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Merus (MRUS), Krystal Biotech (KRYS) and Treace Medical Concepts (TMCI)February 28, 2025 | markets.businessinsider.comMerus (MRUS) Receives a Buy from Stifel NicolausFebruary 28, 2025 | markets.businessinsider.comMerus’s Strategic Advancements and Clinical Progress Justify Buy RatingFebruary 28, 2025 | tipranks.comMerus’s Promising Clinical Advances and Breakthrough Therapy Designation Justify Buy RatingFebruary 28, 2025 | tipranks.comMerus’s Promising Clinical Developments and Regulatory Progress Justify Buy RatingFebruary 27, 2025 | tipranks.comMerus NV (MRUS) Announces Key Developments in Oncology Trials and Financial ResultsFebruary 27, 2025 | gurufocus.comMerus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business UpdateFebruary 27, 2025 | globenewswire.comMerus to Present at Upcoming Investor ConferencesFebruary 25, 2025 | globenewswire.com180,000 Shares in Merus (NASDAQ:MRUS) Bought by Impax Asset Management Group plcImpax Asset Management Group plc purchased a new stake in Merus (NASDAQ:MRUS - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 180,000 shares of the biotechnology company's stock, valued at approxiFebruary 25, 2025 | marketbeat.comMerus (NASDAQ:MRUS) Shares Purchased by HealthInvest Partners ABHealthInvest Partners AB boosted its stake in shares of Merus (NASDAQ:MRUS - Free Report) by 23.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 62,521 shares of the biotechnology company's stock after acquiring an additioFebruary 24, 2025 | marketbeat.comState of New Jersey Common Pension Fund D Buys 10,842 Shares of Merus (NASDAQ:MRUS)State of New Jersey Common Pension Fund D boosted its stake in shares of Merus (NASDAQ:MRUS - Free Report) by 29.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 48,268 shares of the bioFebruary 24, 2025 | marketbeat.comTimesSquare Capital Management LLC Purchases 58,760 Shares of Merus (NASDAQ:MRUS)TimesSquare Capital Management LLC boosted its position in Merus (NASDAQ:MRUS - Free Report) by 21.6% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 331,195 shares of the biotechnology company's stock after purchasing an additional 58,760February 20, 2025 | marketbeat.comMerus’ petosemtamab granted Breakthrough Therapy designation by FDAFebruary 19, 2025 | markets.businessinsider.comMerus’s Breakthrough in HNSCC: Buy Rating Backed by FDA Support and Promising Trial DataFebruary 19, 2025 | tipranks.comMerus NV (MRUS) Receives Second Breakthrough Therapy Designation for Petosemtamab in Head and ...February 19, 2025 | gurufocus.comMerus (MRUS) Expected to Announce Quarterly Earnings on WednesdayMerus (NASDAQ:MRUS) will be releasing earnings before the market opens on Wednesday, February 26.February 19, 2025 | marketbeat.comInnate Pharma and Merus gets FDA Breakthrough Therapy Designation for their respective treatmentsFebruary 18, 2025 | msn.com7MRUS : Merus Shares Are Up Today: What's Going On?February 18, 2025 | benzinga.comPetosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinomaFebruary 18, 2025 | globenewswire.comMerus N.V.'s SWOT analysis: biotech firm's stock poised for growth amid clinical trialsFebruary 17, 2025 | msn.comMerus (NASDAQ:MRUS) Receives Average Rating of "Buy" from AnalystsMerus (NASDAQ:MRUS - Get Free Report) has been given a consensus recommendation of "Buy" by the sixteen brokerages that are presently covering the company, Marketbeat reports. Fourteen analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the comFebruary 16, 2025 | marketbeat.comPiper Sandler Initiates Coverage of Merus N.V. (MRUS) with Overweight RecommendationFebruary 13, 2025 | msn.comMerus initiated with an Overweight at Piper SandlerFebruary 13, 2025 | markets.businessinsider.comPiper Sandler sets $84 target on Merus stock, cites drug potentialFebruary 13, 2025 | msn.comMerus NV (MRUS) to Present at Citi's 2025 Virtual Oncology Leadership SummitFebruary 13, 2025 | gurufocus.comMerus (NASDAQ:MRUS) Coverage Initiated at Piper SandlerPiper Sandler started coverage on Merus in a report on Thursday. They issued an "overweight" rating and a $84.00 target price for the company.February 13, 2025 | marketbeat.comMerus to Present at Citi's 2025 Virtual Oncology Leadership SummitFebruary 13, 2025 | globenewswire.comAnalyst Recommends Buy for Merus Based on Promising Petosemtamab Developments and Revenue PotentialFebruary 13, 2025 | tipranks.comMerus (NASDAQ:MRUS) Given "Buy" Rating at GuggenheimGuggenheim reaffirmed a "buy" rating on shares of Merus in a research report on Wednesday.February 12, 2025 | marketbeat.comFY2024 Earnings Forecast for Merus Issued By Leerink PartnrsMerus (NASDAQ:MRUS - Free Report) - Investment analysts at Leerink Partnrs increased their FY2024 earnings per share (EPS) estimates for Merus in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens now expects that the biotechnology company will post earnings of (February 10, 2025 | marketbeat.comWells Fargo sets $91 target on Merus stock, cites mCRC potentialFebruary 8, 2025 | msn.comMerus initiated with an Overweight at Wells FargoFebruary 8, 2025 | markets.businessinsider.comWells Fargo & Company Begins Coverage on Merus (NASDAQ:MRUS)Wells Fargo & Company started coverage on shares of Merus in a research note on Friday. They issued an "overweight" rating and a $91.00 target price for the company.February 7, 2025 | marketbeat.com Remove Ads Get Merus News Delivered to You Automatically Sign up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter. Email Address MRUS Media Mentions By Week MRUS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MRUS News Sentiment▼0.440.62▲Average Medical News Sentiment MRUS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MRUS Articles This Week▼65▲MRUS Articles Average Week Remove Ads Get Merus News Delivered to You Automatically Sign up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Moderna News Today Genmab A/S News Today Dr. Reddy's Laboratories News Today Viatris News Today Ascendis Pharma A/S News Today Vaxcyte News Today Qiagen News Today Roivant Sciences News Today Sarepta Therapeutics News Today Revolution Medicines News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MRUS) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merus Please log in to your account or sign up in order to add this asset to your watchlist. Share Merus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MRUS Stock Free MRUS Stock Alerts